CONfident Treatment Decisions in Living With Rheumatoid Arthritis

Pilot test the novel educational patient-directed intervention to demonstrate the feasibility of the novel educational approaches developed in improving patient's willingness to achieve remission or low disease activity in RA. Upon agreement to participate, the patient participants will provide information on their treating physician. This information will be used to invite physicians to complete the physician-educational intervention and offered CME credits for completing the activity.

The investigators will recruit participants from a patient registry (1:1 intervention: control) that meet the eligibility criteria. The recruited patients will complete the educational intervention (if randomized to the intervention arm) and the study outcomes will be collected immediately after the intervention and also after the patients most proximate rheumatologist visit (up to 6-months later).

• Other: Patient Educational Intervention
  Patients will view 5-6 videos that will help them with pre-identified patient barriers to achieving RA low disease activity
• Other: Patient Control
  Patients will receive an attention control

• Experimental: Patient Variation 1
  Patient Educational Intervention: Patient will receive intervention videos and will be required to complete the baseline and follow-up surveys.
  Intervention: Other: Patient Educational Intervention
• Experimental: Patient Variation 2
  Patient Control: Patients will receive an attention control and will be required to complete the baseline and follow-up surveys.
  Intervention: Other: Patient Control

Inclusion Criteria:

• Have a patient-reported diagnosis of RA
• Most recent RAPID3 > 12 collected in the last 6 months
• Have not changed RA medication in the last 6 months
• Taking medications that are commonly used in RA (e.g. methotrexate, sulfasalazine, hydroxychloroquine (plaquenil), leflunomide (arava), etanercept (enbrel), adalimumab (Humira), tofacitinib (xeljanz), actemra (tocilizumab), sarilumab (Kevzara) , infliximab (remicade), golimumab (Simponi), rituximab (rituxan), abatacept (Orencia), and certolizumab (Cimzia))

Exclusion Criteria:

• Does not meet inclusion criteria
• Age < 18